In last trading session, MoonLake Immunotherapeutics (NASDAQ:MLTX) saw 0.33 million shares changing hands with its beta currently measuring 1.27. Company’s recent per share price level of $45.99 trading at -$1.13 or -2.40% at ring of the bell on the day assigns it a market valuation of $2.94B. That closing price of MLTX’s stock is at a discount of -41.29% from its 52-week high price of $64.98 and is indicating a premium of 18.35% from its 52-week low price of $37.55. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.61 million shares which gives us an average trading volume of 320.65K if we extend that period to 3-months.
For MoonLake Immunotherapeutics (MLTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.59 in the current quarter.
MoonLake Immunotherapeutics (NASDAQ:MLTX) trade information
Upright in the red during last session for losing -2.40%, in the last five days MLTX remained trading in the green while hitting it’s week-highest on Thursday, 01/30/25 when the stock touched $45.99 price level, adding 3.63% to its value on the day. MoonLake Immunotherapeutics’s shares saw a change of -15.07% in year-to-date performance and have moved 0.63% in past 5-day. MoonLake Immunotherapeutics (NASDAQ:MLTX) showed a performance of -13.26% in past 30-days. Number of shares sold short was 7.8 million shares which calculate 22.54 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 76 to the stock, which implies a rise of 39.49% to its current value. Analysts have been projecting 62 as a low price target for the stock while placing it at a high target of 100. It follows that stock’s current price would drop -34.81% in reaching the projected high whereas dropping to the targeted low would mean a loss of -34.81% for stock’s current value.
MoonLake Immunotherapeutics (MLTX) estimates and forecasts
Statistics highlight that MoonLake Immunotherapeutics is scoring comparatively lower than the scores of other players of the relevant industry. The company added 10.42% of value to its shares in past 6 months, showing an annual growth rate of -146.58% while that of industry is 16.00. Apart from that, the company came lowering its revenue forecast for fiscal year 2025.
MoonLake Immunotherapeutics (NASDAQ:MLTX)’s Major holders
Insiders are in possession of 15.22% of company’s total shares while institution are holding 98.17 percent of that, with stock having share float percentage of 115.79%. Investors also watch the number of corporate investors in a company very closely, which is 98.17% institutions for MoonLake Immunotherapeutics that are currently holding shares of the company. BVF INC/IL is the top institutional holder at MLTX for having 21.75 million shares of worth $956.4 million. And as of 2024-06-30, it was holding 34.7258 of the company’s outstanding shares.
The second largest institutional holder is CORMORANT ASSET MANAGEMENT, LP, which was holding about 8.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 13.5609 of outstanding shares, having a total worth of $373.49 million.
On the other hand, Price (T.Rowe) Health Sciences Fund and Fidelity Select Portfolios – Health Care are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.31 shares of worth $60.16 million or 2.07% of the total outstanding shares. The later fund manager was in possession of 690.0 shares on Nov 30, 2024 , making its stake of worth around $31.73 million in the company or a holder of 1.09% of company’s stock.
